UCB has released an interim report for the first three quarters of 2012 that showcases the strong performance delivered by the company.
The firm's revenues for the nine months came to 2.57 billion euros (2.07 billion pounds), up by five percent thanks largely to the strong growth of the key products Cimzia, Vimpat and Neupro.
Net sales of each of these products rose by double-digit margins, thus helping to compensate for the fall in demand for the epilepsy drug Keppra following the expiry of its patent.
Roch Doliveux, chief executive officer of UCB, said: "UCB has now reached the inflection point where net sales of our new core medicines are higher than those of the Keppra franchise - the 'crossover'."
Revenue for the full year is now expected to exceed 3.2 billion euros, driven by the continued growth of these three drugs.
This comes after the company announced the appointment of Anna Richo as its new executive vice-president and general counsel earlier this month, succeeding the soon-to-retire Bob Trainor.See all the latest jobs in Pharmaceutical